IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
This study has been completed.
Sponsor:
Bayer
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00350051
First received: July 7, 2006
Last updated: December 2, 2014
Last verified: December 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate cancer, who have not had previous chemotherapy, is safe and helps to decrease PSA (Prostate-specific antigen) levels.
| Condition | Intervention | Phase |
|---|---|---|
| Prostate Cancer | Drug: Sagopilone (ZK 219477) + prednisone | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
prostate cancer
Drug Information available for:
Prednisone
U.S. FDA Resources
Further study details as provided by Bayer:
Primary Outcome Measures:
- PSA Response to treatment with ZK-Epo plus prednisone after 6 cycles [ Time Frame: at least 28 days post day 21 of last cycle of treatment ]
Secondary Outcome Measures:
- Safety & Tolerability of ZK-Epo plus prednisone [ Time Frame: until progression, unknown duration ]
| Enrollment: | 53 |
| Study Start Date: | August 2006 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Arm 1 |
Drug: Sagopilone (ZK 219477) + prednisone
Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
|
Detailed Description:
This study has previously been posted by Berlex, Inc. and Schering AG, Germany.Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer HealthCare Pharmaceuticals, Inc.and Bayer Schering Pharma AG, Germany are the sponsors of the trial.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Must have evidence of confirmed metastatic prostate cancer
- Serum testosterone must be less than 50 ng/mL
- Disease must be progressing despite anti-androgen therapy
- PSA level must be elevated
- Additional criteria determined at screening visit
Exclusion Criteria:
- Any previous cytotoxic chemotherapy for prostate cancer
- Use of any investigational drug in the last 4 weeks
- Symptomatic brain tumors requiring radiation to the brain
- Active infection
- Additional criteria determined at screening visit
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00350051
Please refer to this study by its ClinicalTrials.gov identifier: NCT00350051
Locations
| United States, California | |
| Fountain Valley, California, United States, 92708 | |
| United States, Florida | |
| Sarasota, Florida, United States, 34237 | |
| United States, Maryland | |
| Baltimore, Maryland, United States, 21201 | |
| United States, Michigan | |
| Ann Arbor, Michigan, United States, 48109-0330 | |
| United States, Montana | |
| Billings, Montana, United States, 59101 | |
| United States, Nebraska | |
| Omaha, Nebraska, United States, 68198 | |
| United States, New York | |
| Bronx, New York, United States, 10469 | |
| United States, Ohio | |
| Canton, Ohio, United States, 44718 | |
| United States, Oregon | |
| Portland, Oregon, United States, 97201-2999 | |
| United States, Pennsylvania | |
| Altoona, Pennsylvania, United States, 16601 | |
| United States, Texas | |
| Fort Worth, Texas, United States, 76104 | |
| United States, Washington | |
| Seattle, Washington, United States, 98108-1597 | |
| Argentina | |
| Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1280AEB | |
| Buenos Aires, Argentina, 1406FWY | |
| Buenos Aires, Argentina, C1405DCS | |
| Buenos Aires, Argentina, C1416CRJ | |
| Córdoba, Argentina, X5016KEH | |
Sponsors and Collaborators
Bayer
Investigators
| Study Director: | Bayer Study Director | Bayer |
More Information
Additional Information:
Publications:
| Responsible Party: | Bayer |
| ClinicalTrials.gov Identifier: | NCT00350051 History of Changes |
| Obsolete Identifiers: | NCT00430222 |
| Other Study ID Numbers: |
91500 307976 ( Other Identifier: Company internal ) |
| Study First Received: | July 7, 2006 |
| Last Updated: | December 2, 2014 |
Keywords provided by Bayer:
|
Prostate cancer Metastatic androgen-independent prostate cancer |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Prednisone |
Androgens Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents |
ClinicalTrials.gov processed this record on August 18, 2017